Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

Novartis Pharmaceuticals297 enrolled

Overview

This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab. Patients who were prescribed crizanlizumab were included in the cohort.

Study Type

OBSERVATIONAL

Enrollment

297

Conditions

Sickle Cell Disease

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion criteria: * Any patient with diagnosis of SCD based on high-performance liquid chromatography (HPLC) or hemoglobin electrophoresis at treating institution * Treatment order for crizanlizumab; Index date was defined as the date for the first crizanlizumab treatment * At least 12 months of available electronic medical record (EMR) data pre-index date (baseline) * Patients must have received at least one dose of crizanlizumab * For inclusion in pre/post analysis of effectiveness, patients must have received at least 6 doses of medication. The rates could be annualized if total post-index time was \<12 months. Exclusion criteria: None specified

Locations (11)

University of Alabama Birmingham

Birmingham, Alabama, United States

Cristiana Care

Wilmington, Delaware, United States

All Children's Hospital

St. Petersburg, Florida, United States

Outcomes

Primary Outcomes

Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) prior to treatment with crizanlizumab

Time frame: Up to 12 months

Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) during treatment with crizanlizumab

Time frame: Up to 12 months

Secondary Outcomes

Number of patients who discontinued treatment with crizanlizumab

Time frame: Up to 24 months

Number of doses of crizanlizumab for patients who discontinued treatment with crizanlizumab

Time frame: Up to 24 months

Reasons for early discontinuation of crizanlizumab treatment

Time frame: Up to 24 months

Number of sickle cell disease (SCD)-related hospitalizations

Time frame: Up to 24 months

Number of SCD-related emergency department (ED) visits

Time frame: Up to 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.